Lady Davis Institute

Lady Davis Institute. It is a major biomedical research center affiliated with the Jewish General Hospital in Montreal, Quebec. Founded in 1969, it is named for the wife of philanthropist Sir Mortimer B. Davis. The institute is dedicated to advancing knowledge in areas such as cancer, aging, neuroscience, and infectious diseases through fundamental and clinical research.

History

The institute was established in 1969 through a significant endowment from the Davis family, honoring Lady Henrietta Davis. It was created to expand the research mission of the Jewish General Hospital, which itself was founded in 1934. Early leadership, including figures like Dr. Henry Kamin, helped establish its scientific credibility. Over decades, it grew from a small unit into a large, multidisciplinary facility, notably expanding its physical space with the construction of the Bloomfield Centre for Research in Aging in the 1990s. Its history is intertwined with the growth of Montreal's academic health network, maintaining close ties with McGill University.

Research focus

Primary research is organized into several thematic axes. Cancer research encompasses studies on leukemia, breast cancer, and ovarian cancer, focusing on molecular mechanisms and novel therapies. The aging and neurodegenerative diseases axis investigates conditions like Alzheimer's disease and Parkinson's disease, often through the Bloomfield Centre for Research in Aging. Research in immunology and infectious diseases addresses HIV/AIDS, influenza, and emerging pathogens. Additional strengths include cardiovascular and metabolic diseases, psychiatric disorders, and population health, utilizing advanced techniques in genomics and epidemiology.

Affiliations and partnerships

It operates as the research arm of the Jewish General Hospital, part of the Integrated University Health and Social Services Centre network. It holds a formal academic affiliation with the Faculty of Medicine at McGill University, with many scientists holding cross-appointments. Key partnerships include the Canadian Institutes of Health Research, the National Institutes of Health, and the Cancer Research Society. It also collaborates extensively with other Montreal institutions like the Montreal Neurological Institute and the Research Institute of the McGill University Health Centre.

Notable achievements and discoveries

Researchers pioneered the development of 3TC (lamivudine), a cornerstone antiviral drug for treating HIV/AIDS and hepatitis B. In cancer research, teams made seminal discoveries in the genetics of leukemia, contributing to targeted therapies. Work on the BRCA1 and BRCA2 gene mutations in hereditary breast and ovarian cancer has been internationally recognized. Neuroscientists have advanced the understanding of tau protein pathology in Alzheimer's disease. The institute's epidemiologists have also produced influential population studies on the health effects of the Ice Storm of 1998.

Leadership and organization

The institute is led by a Scientific Director, a position long held by geneticist Dr. Rima Rozen. Governance involves a Board of Directors and scientific advisory committees. It is structured into interdisciplinary research divisions rather than traditional departments, fostering collaboration. The institute trains numerous postdoctoral fellows and graduate students through its McGill affiliation. Key operational units include shared core facilities for flow cytometry, biostatistics, and genomic sequencing, supporting the work of over 200 independent researchers and their teams.

Category:Medical research institutes in Canada Category:Organizations based in Montreal Category:McGill University Category:1969 establishments in Quebec